Physician profile
Brandy Martinez
NPI 1235875527
$19,961.57
in general payments reported to CMS, 2019-2025
33 companies · $6,320 in 2025
The $6,320 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $6,451 · 2024: $7,191 · 2025: $6,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,954.05 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,012.54 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,966.61 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $1,842.40 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,773.70 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Neurocrine Biosciences, INC. | $1,597.94 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,596.69 | 2023-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,522.07 | 2023-2025 | |
| Lundbeck LLC | $1,281.53 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $747.12 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $723.73 | 2023-2025 | Azstarys |
| Alkermes, INC. | $646.90 | 2023-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $594.33 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $542.13 | 2023-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $529.93 | 2024-2025 | Qelbree |
| Indivior INC. | $456.44 | 2023-2025 | Perseris, Sublocade |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $407.18 | 2024-2025 | Cobenfy |
| Biogen, INC. | $257.84 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $242.16 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $236.61 | 2023-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Bausch Health US, LLC | $221.98 | 2023-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $155.30 | 2023-2025 | Quviviq, Quviviq |
| Braeburn INC. | $128.90 | 2025 | Brixadi |
| Uswm, LLC | $125.91 | 2023-2024 | Lucemyra, Zimhi |
| Avadel Cns Pharmaceuticals, LLC | $88.95 | 2025 | Lumryz |
| Avion Pharmaceuticals | $73.45 | 2023-2024 | Methylphenidate Hydrochloride |
| Tris Pharma INC | $46.55 | 2024 | Dyanavel Xr |
| Azurity Pharmaceuticals, INC. | $25.31 | 2023 | Horizant |
| Vertical Pharmaceuticals, LLC | $24.52 | 2024 | Relexxii |
| Merck Sharp & Dohme LLC | $21.88 | 2023 | Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.69 | 2025 | Rejoyn |
| Collegium Pharmaceutical, INC. | $17.60 | 2025 | Jornay Pm |
| Novo Nordisk INC | $16.12 | 2023 | |
| Lilly USA, LLC | $15.56 | 2024 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.